Exendin-4 dose-dependently stimulates somatostatin and insulin secretion in perfused rat pancreas

Hormone and Metabolic Research

Volumn 36, Issue 9, 2004, Pages 595-600

  Egido, E M ^a   Silvestre, R A ^a   Hernandez R ^a   Marco, J ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Exendin 4; Insulin secretion; Pancreatic somatostatin secretion

Indexed keywords

ARGININE; CARBACHOL; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; MERCAPTAMINE; SOMATOSTATIN;

ARTICLE; B LYMPHOCYTE; CELL FUNCTION; DOSE RESPONSE; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PRIORITY JOURNAL; RAT; SOMATOSTATIN CELL; SOMATOSTATIN RELEASE;

ANIMALS; ARGININE; CARBACHOL; CYSTEAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; INSULIN; MALE; PANCREAS; PEPTIDES; PERFUSION; RATS; RATS, WISTAR; SOMATOSTATIN; SOMATOSTATIN-SECRETING CELLS; VENOMS;

EID: 7644243354     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-825921     Document Type: Article

References (38)

1. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405
2. Coke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting B-cells. J Biol Chem 1993; 268: 19650-19655
3. Rodriguez-Gallardo J, Silvestre RA, Egido EM, Marco J. Insulin secretory pattern induced by exendin-4. Study in the perfused rat pancreas. Diabetologia 2000; 43: A138
4. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001; 50: 583-589
5. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 1282-1290
6. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide or exendin-4. Diabetes 2002; 51: 1443-1452
7. Chepurny OG, Hussain MA, Holz GG. Exendin-4 as a stimulator of rat insulin 1 gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220. Endocrinology 2002; 143: 2303-2313
8. Silvestre RA, Rodriguez-Gallardo J, Egido EM, Marco J. Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur J Pharmacol 2003; 469: 195-200
9. Gedulin B, Jodka L, Hoyt J. Exendin-4 (AC2993) decreases glucagon secretion during hyperglycemic clamps in diabetic fatty Zucker rats. Diabetes 1999; 48: A199
10. Baron A, Fineman M, Young A, Gaines E, Prickett K. Synthetic exendin-4 (AC2993) reduces post-prandial glycaemia, glucagon levels and slows gastric emptying in subjects with type 2 diabetes. Diabetologia 2000; 43: A190
11. Kolterman O, Gottlieb A, Prickett K, Gaines E, Young A. Dose-response for inhibition of glucagon secretion and gastric emptying by synthetic exendin-4 (AC2993) in subjects with type 2 diabetes. Diabetes 2000; 49: A114
12. Parkes DG, Gedulin B, Smith P, Young A. Effect of exendin-4 on glucagon secretion in lean and obese Zucker (ZDF) rats. Diabetes 2001; 50: A313
13. Rodríguez-Gallardo J, Egido EM, Gutiérrez E, Garcia P, Silvestre RA, Marco J. Evidence for a direct inhibitory effect of exendin-4 on alpha-cell secretion. Diabetologia 2002; 45: A214
14. Greig NH, Holloway HW, De Ore KA. One-daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentration. Diabetologia 1999; 42: 45-50
15. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hanse B, Denaro M. Glucose-lowering and insulin sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48: 1026-1034
16. Szayna M, Doyle ME, Betkey JA, Holloway HN, Spencer RG, Greig NH, Egan JM. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936-1941
17. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide or exendin-4. Diabetes 2002; 51: 1443-1452
18. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneaous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003; 284: E1072-1079
19. Eissele R, Bothe-Sandfort E, Göke B, Eng J, Arnold R, Koop H. Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide. Life Sci 1994; 55: 629-634
20. Silvestre RA, Miralles P, Moreno P, Villanueva ML, Marco J. Somatostatin, insulin and glucagon secretion by the perfused rat pancreas from the cysteamine-treated rats. Biochem Biophys Res Commun 1986; 134: 1291-1297
21. Herbert V, Lau KS, Gottlieb CW, Bleicher SJ. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965; 25: 1375-1384
22. Kieffer TJ, Mclntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596
23. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835
24. Parkes DG, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, Young A. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 2001; 53: 260-267
25. Drucker DJ. Glucagon-like peptides. Diabetes 1998; 47: 159-169
26. Ørskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992; 35: 701-711
27. Holz GG, Kühtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature 1993; 361: 362-365
28. Drucker DJ, Phillippe J, Mojsov S, Chick WL, Haberner JF. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987; 84: 3434-3438
29. Blachier F, Mourtada A, Sener A, Malaisse AJ. Stimulus-secretion coupling of arginine-induced insulin release. Uptake of metabolized and nonmetabolized cationic amino acids by pancreatic islets. Endocrinology 1989; 124: 134-141
30. Zawalich WS. Regulation of insulin secretion by phosphoinositide-specific phospholipase V and protein kinase C activation. Diabetes Review 1996; 4: 160-176
31. Samols E, Stagner JI, Ewart RBL, Marks V. The order of islet microvascular cellular perfusion is B>A>D in the perfused rat pancreas. Clin J Invest 1988; 82: 350-353
32. Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993; 42: 1678-1682
33. Fehmann HC, Haberner JF. Functional receptors for the insulinotropic hormone glucagon-like peptide-1-(7-37) on a somatostatin secreting cell line. FEBS Lett 1991; 279: 335-340
34. Gros L, Thorens B, Bataille D, Kervran A. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 1993; 133: 631-638
35. Göke R, Cole T, Conlon JM. Characterization of the receptor for glucagon-like peptide-1 (7-36) amide on plasma membranes from rat insulinoma-cells by covalent cross-linking. J Mol Endocrinol 1989; 2: 93-98
36. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide 1 receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 1997; 46: 785-791
37. Horsck D, Coke R, Eissele R, Michel B, Coke B. Repriprocal cellular distribution of glucagon-like peptide-1 (GLP-1) immunoreactivity and GLP-1 receptor mRNA in pancreatic islet of rat. Pancreas 1997; 14: 290-294
38. Thorens N. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641-8645